GILD - Gilead Sciences, Inc.
| Previous Close | 68.20 |
| Open | 68.03 |
| Bid | 67.73 x 800 |
| Ask | 67.74 x 1300 |
| Day's Range | 67.66 - 68.40 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 1,826,302 |
| Avg. Volume | 6,629,518 |
| Market Cap | 86.109B |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | 14.94 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.52 (3.87%) |
| Ex-Dividend Date | 2019-06-13 |
| 1y Target Est | N/A |
- Business Wire•5 hours ago
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. Nurix’s technology platform is focused on the manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells.
- Business Wire•16 days ago
Kite Announces New Yescarta® Data From ZUMA-1
-- Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment --
- Business Wire•18 days ago
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
ZUMA-3 is a single-arm Phase 1/2 study in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The results provide guidance on dosing and safety management for KTE-X19 to inform the ongoing Phase 2 study. Patients enrolled in this study were primary refractory or relapsed/refractory after at least two prior lines of therapy.
- GlobeNewswire•18 days ago
Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies
Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company (a pharmaceutical company engaged in the development of innovative cancer cell therapies). The agreement is aimed at the development of molecular-based assays on Biocartis` molecular diagnostics Idylla(TM) platform that are supportive to Kite`s therapies.
- GlobeNewswire•19 days ago
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Kite will act as the sponsor of this study and will be responsible for its conduct. GM-CSF has been identified, through clinical correlative analysis and preclinical modeling, as a potential key signal in the inflammatory cascade triggering toxicities associated with chimeric antigen receptor T (CAR T) cell therapy.1 Toxicities associated with CAR T therapy include neurologic toxicity and cytokine release syndrome (CRS).
- Business Wire•19 days ago
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kite, a Gilead Company (GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Kite will act as the sponsor of this study and will be responsible for its conduct. GM-CSF has been identified, through clinical correlative analysis and preclinical modeling, as a potential key signal in the inflammatory cascade triggering toxicities associated with chimeric antigen receptor T (CAR T) cell therapy.1 Toxicities associated with CAR T therapy include neurologic toxicity and cytokine release syndrome (CRS).
- GlobeNewswire•21 days ago
GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Foster City, Calif. and Mechelen, Belgium; May 29, 2019; 22.30 CET ...
- Business Wire•21 days ago
Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.
- Business Wire•21 days ago
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
Gilead Sciences, Inc. (GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company’s senior leadership team. Ms. Mercier will assume responsibility for the company’s commercial operations effective July 1. Laura Hamill, Executive Vice President Worldwide Commercial Operations, will be departing from Gilead.
- CNW Group•22 days ago
Grants awarded to 11 Canadian initiatives to support the elimination of chronic hepatitis C infection in high-risk populations
Grants awarded to 11 Canadian initiatives to support the elimination of chronic hepatitis C infection in high-risk populations
- Business Wire•29 days ago
Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5
Webcast Available Through Gilead Corporate Website
- Business Wire•last month
Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019
-- New Safety Data Involving Steroid Use and New Subpopulation Analyses from Pivotal ZUMA-1 Trial to Provide Greater Understanding of Yescarta® in Patients with Relapsed or Refract
- Business Wire•last month
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
Gilead Sciences, Inc. (GILD) today announced that it will donate Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV and end the epidemic. This medication donation is among the largest ever in the United States and is part of Gilead’s broader ongoing initiatives to help ensure that everyone who can benefit from PrEP is able to access it. Gilead will provide to CDC up to 2.4 million bottles of Truvada® annually for uninsured Americans at risk for HIV.
- Business Wire•last month
Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease
Gilead Sciences, Inc. (GILD) and Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, today announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™ (KGA), a comprehensive registry of patients with kidney diseases integrating genomic, transcriptomic and proteomic data with patient clinical profiles.
- Business Wire•last month
Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14
Webcast Available Through Gilead Corporate Website
- Business Wire•2 months ago
Gilead Sciences Announces Second Quarter 2019 Dividend
Gilead Sciences, Inc. today announced that the company’s Board of Directors has declared a cash dividend of $0.63 per share of common stock for the second quarter of 2019.
- Business Wire•2 months ago
Gilead Sciences Announces First Quarter 2019 Financial Results
- Product Sales of $5.2 billion -- Diluted EPS of $1.54 per share -- Non-GAAP Diluted EPS of $1.76 per share -- Reiterates Full Year 2019 Guidance -
- Business Wire•2 months ago
Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020
Gilead Sciences, Inc. (GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020. Ms. Washington will continue as EVP and CFO while the company works to identify a successor. Should a CFO be named before March 1, 2020, Ms. Washington has agreed to remain in an advisory capacity through the completion of the company’s reporting of 2019 financial results to ensure a smooth transition.
- Business Wire•2 months ago
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH. In the study of 802 enrolled and dosed patients, 9.3 percent of patients treated with selonsertib 18 mg (p=0.42 versus placebo) and 12.1 percent of patients treated with selonsertib 6 mg (p=0.93) achieved a ≥ 1-stage improvement in fibrosis according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment, versus 13.2 percent with placebo.
- Business Wire•2 months ago
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities
Kite, a Gilead Company , today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T therapies, including Yescarta® , Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor ...
- Business Wire•2 months ago
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019
Gilead Sciences, Inc. (GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update.
- Business Wire•2 months ago
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
Gilead Sciences Inc. (GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro models and drive therapeutic discovery and development.
- Business Wire•2 months ago
Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
Gilead Sciences, Inc. (GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof of concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH. The companies are also exploring the potential to collaborate on preclinical research to advance understanding of the disease.